Dew, how do you know this, and how do you define definitely ?
I would never presume to speak for Dew, but don't you think it is kind of obvious? There is no indication that there is anything substantive that's wrong with the production methodology, the "test" drug's DIS-approval rests mostly on fairly thin split hairs (i.e. the belief that a non-trivial possibility exists that ATryn administration for at-term women is unmanageable because of (a) poorly-defined protocols and/or (b) some degree of unpredictability in those patients' response to ATryn). Pharming is pursuing essentially the same business model, albeit with other species. Barring the ultra-rapid development and approval for a competing process, the main risks apart from a socio-political backlash are funding and expertise, both of which are enhanced by such a merger.
Interest - highly likely. Consummation - who knows...
Market Data 
Markets 
AI
